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USE OF CONJUGATE BIOTECHNOLOGY 
TO IMPROVE THERAPEUTIC OPTIONS 
Anthony H. Gershlick, BSc, FRCP 
University of Leicester 
Leicester, United Kingdom 
For all therapeutic options local drug delivery 
should in theory be the preferred way of ensuring 
adequate drug is delivered to the pathological site 
without the risks of side effects. It  would appear illog- 
ical to administer a drug systemically to treat perhaps 
only 20 to 30 mm of the coronary artery. Large sys- 
temic doses may be required to achieve adequate 
doses of drug locally, with the risk of systemic side 
effects. Sometimes agents hown to be effective in sys- 
temic doses in an animal model cannot be given to 
man in the same dose or are shown in clinical trials as 
a result o be ineffective. A good example was the lack 
of efficacy of ACE inhibitors in human trials ofangio- 
plasty restenosis despite their proven value in the rat 
and rabbit models: the dose effective in the model was 
10 times that which could be tolerated by man. It 
would have been better to have calculated the dose 
required locally and to have delivered that locally. 
Local drug delivery can be achieved using appropri- 
ately designed balloons. A number of  these and a 
number of agents have been extensively investigated 
in vitro and in animal studies. There are three major 
problems with local drug delivery. First, it is not local; 
many studies have shown that regional distribution f 
an agent occurs. Thus drug delivered to the coronary 
arteries could affect myocardial cell function. Second, 
efficiency of delivery is poor, with only 2% to 5% of 
drug being delivered to the site. Part of this is loss of 
drug from the device and part is lack of retention. 
While it is always difficult to determine how much (or 
how little) drug is needed locally, such studies do at 
least suggest hat the majority of drug (> 95%) is not 
locally retained and is therefore in the systemic ircu- 
lation. The final major problem is the lack of retention 
itself. There appears no reason, except for the passive 
adsorption of  antibodies to smooth muscle cells for 
example, for the drug to stay where it is delivered. 
In our laboratory we have, over a number of  
years, explored the possibility of improving reten- 
tion and therefore fficacy of drugs delivered locally 
by the development of conjugates. Our initial work 
developed the concept of targeting through the use 
of  localizing agents. Thus a conjugate would in 
effect be the combination of a localizing agent, usu- 
ally an antibody directed against a particular compo- 
nent of  the vessel wall, that was expressed by the 
pathological process, combined through a chemical 
process to the effector agent, a lower than systemic 
dose of the active drug. Initial studies assessed an 
antibody against damaged vessel wall (P14Gl l )  
conjugated using SPDP to a glycoprotein I Ib /U Ia  
receptor blocker. Delivering this conjugate with an 
LDD balloon not only reduced restenosis in an in 
vivo model of angioplasty at a dose seven times less 
than would have been required systemically, but 
measures of systemic effects were not seen. 
Since this early work we have been studying the 
development of  bispecific antibodies. Such mole- 
cules are formed by choosing the two antibodies: 
one localizing and one ffector. These antibodies are 
deconstructed enzymatically, and two monovalent 
Fabs of the separate antibodies are recombined by 
reestablishing the interheavy chain disulphide 
bonds. Thus we have prepared a novel bispecific 
molecule with one arm being the monovalent Fab of  
a glycoprotein I Ib / I I I a  receptor blocker and the 
other the monovalent Fab of  an antibody (AP1) 
JOURNAL OF VASCULAR SURGERY 
Volume 31, Number 6 Lifeline Research Meeting Abstracts 1297 
against expressed tissue factor. In vitro and in vivo 
testing of this molecule suggests it retains the prop- 
erties of both parents and has enhanced effect on 
retention of the glycoprotein I Ib / I I Ia  receptor 
blocker compared with the receptor blocker alone. 
Methods 
Murine antirabbit GPIIb/ I I Ia receptor antibody 
(AZ-1) was conjugated with the antirabbit issue 
factor antibody (AP-1) using chemical recombination 
of antibody fragments. The activity of this novel bispe- 
cific product was tested using platelet aggregometry 
and in a clotting assay designed to measure the 
inhibitory effects on platelet GPIIb/I I Ia receptors and 
tissue factor espectively. In an ex vivo model the con- 
jugate was delivered to rabbit aorta segments using a 
microporous infusion catheter (Cordis Corporation, 
US). The conjugate was mounted in a perfusion cir- 
cuit to measure retention over 12 hours compared 
with the original anti-GPIIb/IIIa antibody. 
Results 
The conjugate inhibited a enosine diphosphate 
(ADP) induced platelet aggregation almost com- 
pletely at a concentration of45 btg per 108 platelets. 
It also prolonged tissue factor induced clotting time 
fourfold at a concentration of 6.5 btg/mL. The 
retention of  the conjugate was enhanced; 21.8% 
remained in the vessel segments after 12 hours com- 
pared with 10.6% in the control group (P < .05). 
Conclusion 
It is possible to construct a conjugate of anti- 
GPI Ib/ I I Ia  and tissue factor antibodies that retain 
biological function and have together enhanced 
retention in the vessel wall. 
Ongoing in vivo studies and future trials will be 
presented. 
Our goal is to identify for any specific process anew 
antigen or exposure of previously hidden vessel wall 
component that will allow us to construct molecules 
that can be delivered systemically in less than normal 
systemic doses such that they target he pathology, the 
so called "magic bullet." Dealing with the problems of 
thrombolysis resistance, thrombolytic failure, and reoc- 
clusion are the current aims of our studies. 
DEVELOPMENTS IN  CATHETER 
TECH-NOLOGIES  
Steven Bailey, MD, FACC 
University of Texas Health Sciences Center at San Antonio 
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Percutaneous coronary interventions, despite the 
use of endovascular stents, s ill have limitations due 
to early thrombotic events as well as late neointimal 
proliferation. 1-4 Thrombus formation has been 
aggressively addressed using new oral and intra- 
venous systemic antiplatelet therapy and improved 
flow with stcnts. S-7 Despite these newer therapies 
there are still major problems such as acute 
myocardial ischemia and saphenous vein graft 
degeneration. 8-1° Progressive disease in saphenous 
vein grafts is often with a friable and thrombotic 
base that continues to represent a challenging sce- 
nario for percutaneous interventions. Local delivery 
of pharmacologic agents is now possible using 
catheters pecifically designed for regional or site 
specific delivery)l, ~2 These catheters have been 
developed to allow an increased volume of agent o 
be infused at a chosen site in an arterial segment. 
With the use of the properties of passive diffusion or 
active infusion, these catheters will deliver pharma- 
ceuticals or genes into the arterial wall. 
Clinical approaches have used the ability of the 
new catheters to approach this problem in one of 
three techniques: (1) low-pressure diffusion, (2) low 
volume infusion, or (3) direct injection into the 
artery wall or pericardium. 
While each catheter system has its own unique 
characteristics, the current delivery systems have 
equivalent efficiencies of approximately 0.1% to 
1.0%.13 While low, this still represents nearly a 100- 
fold increase over that seen with systemic adminis- 
tration or infusion through a guide catheter. The 
limiting problem has not been identifying a delivery 
catheter but determining what pharmaceutical agent 
should be administered and what specific clinical 
problem we are treating. 
Coronary dissection and thrombus formation 
resulting in acute and subacute vessel closure remain 
significant problems. 14 The decision of which agents 
to use for local delivery centered on those agents with 
prior FDA approval. The widespread availability of 
thrombolytic and antiplatelet therapies resulted in the 
early use of these agents for local administration. The 
Dispatch catheter was one of the first systems evaluat- 
ed in the clinical arena as a local administration device 
for the indication of coronary thrombus. A nondilat- 
ing catheter that allows antegrade blood flow while the 
drug infusion was occurring it also offered the oppor- 
nmity for prolonged administration fagents without 
causing myocardial ischemia. This catheter was exten- 
sively characterized in humans by Camenzind et all5 in 
a novel and elegant manner. Using a continuous infu- 
sion of tracer that did not have myocardial uptake with 
rapid clearance (MAG-3), these authors were able to 
demonstrate that the actual site of administration 
